Government Spending Bill Extends Deadline for Filing COVID-19 Injury Claims
A new U.S. government spending bill will extend the time for those injured by the COVID-19 shot to file for federal vaccine injury compensation under the Countermeasures Injury Compensation Program (CICP). Under the bill, certain claimants previously denied compensation will be permitted to refile their claims. under the bill, as well. The continuing resolution bill […]
Russia Develops mRNA Cancer Biologic
Russia’s Ministry of Health announced last week that it has developed an mRNA (messenger ribonucleic acid) therapeutic biologic for cancer. A name for the shot has not yet been revealed, but it will cost the government about 300,000 rubles per dose—the equivalent of $2,869. The mRNA cancer biologic will be made available to the public […]
COVID Shots Injury Claims May Take Up to a Decade to Settle
A recent report released by the Select Subcommittee on the Coronavirus Pandemic Committee on Oversight and Accountability by the U.S. House of Representatives on Dec. 4, 2024 revealed that the Countermeasures Injury Compensation Program (CICP) is deeply flawed. Unless the system is drastically overhauled, it may take up to 10 years to process the existing […]
Three German Scientists Call for Immediate Halt on All mRNA Biologicals, Including COVID Shots
German authors of a new peer-reviewed study called for an “immediate halt of all mRNA biologicals,” ” including COVID-19 shots, until questions about residual DNA that well exceeds regulatory limits can be answered. The study, published on Dec. 3, 2024 in the Public Health Policy Journal, underscores concerns about the mRNA technology that includes the […]
Gates Foundation Awards $8.6 Million to Expand Development of Multi-Dose Pediatric Vaccines Using Novel Adjuvants
On Dec. 5, 2024, formulation technology company VitriVax, Inc. of Boulder, Colorado was awarded a two-year, $3.6 million grant by the Bill & Melinda Gates Foundation to help “fund development of a polio vaccine formulation for possible inclusion in combination pediatric vaccines.” “We are honored to be part of the global drive to protect children […]
First Needle-Free Patch RSV Vaccine Being Created
The U.S. National Institutes of Health (NIH) has granted the Biotech company Vaxxas Pty. Ltd. of Australia a worldwide license to a respiratory syncytial virus (RSV) antigen known as DS2. The license will allow for the firm to create the first needle-free and room-temperature stable RSV vaccine using a novel and “cutting edge” high-density microarray […]